Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab vs Intensive Statin in Cerebral Atherosclerosis (HERALD)
NCT05585151Phase 4Recruiting
- Start
- Nov 2022
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of evolocumab in cerebral atherosclerosis. Started Nov 2022; status: recruiting.
02
Drugs
evolocumab
03
Conditions
cerebral atherosclerosis
Beyond the preview
Go deeper on NCT05585151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05585151.